Susan Hicks
Directeur Général chez Technology Venture Corp.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jack Stewart | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 19 ans |
Paul Gunn | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 19 ans |
Vaughn Embro-Pantalony | M | 66 |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 6 ans |
Tom Reeves | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
Marc Rubin | M | 69 |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 6 ans |
Robert Bruce | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | 5 ans |
Camille Belliveau | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Kenneth N. Keirstead | M | - |
Soricimed Biopharma, Inc.
Soricimed Biopharma, Inc. BiotechnologyHealth Technology Soricimed Biopharma, Inc. develops novel cancer therapeutics and diagnostics. Its programs include SOR-C13 and Peptide-Drug Conjugate. The company was founded by Jack Stewart and Paul Gunn in 2005 and is headquartered in Moncton, Canada. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Susan Hicks
- Réseau Personnel